These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17466449)

  • 1. Editorial comment on: Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
    Babjuk M
    Eur Urol; 2007 Nov; 52(5):1396-7. PubMed ID: 17466449
    [No Abstract]   [Full Text] [Related]  

  • 2. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
    Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
    Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical implications of urine matrix metalloproteinases and their inhibitors in patients with chronic glomerulonephritis].
    Li OA; Bobkova IN; Kozlovckaia LV
    Ter Arkh; 2009; 81(8):10-4. PubMed ID: 19799193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers.
    Sier CF; Casetta G; Verheijen JH; Tizzani A; Agape V; Kos J; Blasi F; Hanemaaijer R
    Clin Cancer Res; 2000 Jun; 6(6):2333-40. PubMed ID: 10873084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in the urine of children with pyelonephritis].
    Tenderenda E; Zoch-Zwierz W; Wasilewska A; Porowski T; Taranta-Janusz K; Kołodziejczyk Z; Michaluk-Skutnik J
    Pol Merkur Lekarski; 2009 Jul; 27(157):10-3. PubMed ID: 19650421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors.
    Di Carlo A; Terracciano D; Mariano A; Macchia V
    Oncol Rep; 2006 May; 15(5):1321-6. PubMed ID: 16596205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correspondence re: C. F. M. Sier et al., Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin. Cancer Res., 6: 2333-2340, 2000.
    Gerhards S; Jung K; Koenig F; Daniltchenko D; Hauptmann S; Schnorr D; Loening SA
    Clin Cancer Res; 2001 Feb; 7(2):445-7. PubMed ID: 11234903
    [No Abstract]   [Full Text] [Related]  

  • 8. Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival.
    Offersen BV; Knap MM; Horsman MR; Verheijen J; Hanemaaijer R; Overgaard J
    Acta Oncol; 2010 Nov; 49(8):1283-7. PubMed ID: 20843171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MMP-2 and MMP-9 as prognostic markers for the early detection of urinary bladder cancer.
    Fouad H; Salem H; Ellakwa DE; Abdel-Hamid M
    J Biochem Mol Toxicol; 2019 Apr; 33(4):e22275. PubMed ID: 30548095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer.
    Ramón de Fata F; Ferruelo A; Andrés G; Gimbernat H; Sánchez-Chapado M; Angulo JC
    Actas Urol Esp; 2013 Sep; 37(8):480-8. PubMed ID: 23916137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
    Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
    Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection.
    Gohji K; Fujimoto N; Fujii A; Komiyama T; Okawa J; Nakajima M
    Cancer Res; 1996 Jul; 56(14):3196-8. PubMed ID: 8764105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer.
    Vasala K; Turpeenniemi-Hujanen T
    Clin Biochem; 2007 Jun; 40(9-10):640-4. PubMed ID: 17374529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
    Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
    Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
    Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
    Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study.
    Amati M; Tomasetti M; Scartozzi M; Mariotti L; Alleva R; Pignotti E; Borghi B; Valentino M; Governa M; Neuzil J; Santarelli L
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):163-70. PubMed ID: 18199721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression.
    O'Grady A; Dunne C; O'Kelly P; Murphy GM; Leader M; Kay E
    Histopathology; 2007 Dec; 51(6):793-804. PubMed ID: 18042068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.
    Roy R; Louis G; Loughlin KR; Wiederschain D; Kilroy SM; Lamb CC; Zurakowski D; Moses MA
    Clin Cancer Res; 2008 Oct; 14(20):6610-7. PubMed ID: 18927302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer.
    Szarvas T; Singer BB; Becker M; Vom Dorp F; Jäger T; Szendroi A; Riesz P; Romics I; Rübben H; Ergün S
    BJU Int; 2011 Apr; 107(7):1069-73. PubMed ID: 20825402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
    Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
    Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.